The oxygen therapy is an universal treatment in the hospital setting, especially in the critical care units. The purpose of this therapy is to avoid hypoxemia and to ensure an adequate supply of oxygen to the tissues. But often we overlook the potential adverse effects of oxygen therapy. Oxygen produces lung damage and induces apoptosis and cell death creating an imbalance between the productio...

T he concept that a catheter could be used for intracardiac therapy was first put into practice in 19641 with the dilation of acquired peripheral vascular stenosis by graduated rigid dilators. Isolated cases of intracardiac therapy with a catheter had appeared as early as 19532; however, the balloon atrial septostomy developed by Dr. Rashkind and reported in 19663 was the first pediatric and th...

The purpose and objectives of this exploratory descriptive study were threefold: to assess the impact of pet-assisted therapy on the overall well-being of behavioral health staff, to document whether pet-assisted therapy affected the retention of behavioral health staff, and to explore and describe therapeutic measures behavioral health staff implemented in using pet-assisted therapy in the del...

Recent therapeutic innovations are significantly changing the management of young children with severe haemophilia. A team from University Hospital Nice (06) introduced emicizumab, first subcutaneous non-replacement therapy. Integrated into multi-professional and their families, this innovative option has shown encouraging initial results. Experience sharing.

Administration of bone marrow-derived mesenchymal stem cells (MSCs) is an innovative approach for the treatment of a range of diseases that are not curable by current therapies including heart failure. A number of clinical trials have been completed and many others are ongoing; more than 2,000 patients worldwide have been administered with culture-expanded allogeneic or autologous MSCs for the ...

The 12 previous volumes in this series are: 1999 – Combination DMARD therapy in rheumatoid arthritis 2000 – Bone mass in the rheumatic diseases 2001 – Controversies in COX-2 inhibitor therapy 2002 – Innovative therapies for spondyloarthritides 2003 – Early arthritis 2004 – Benefit/risk of new drugs for rheumatoid arthritis 2005 – Quantitative clinical assessment of rheumatic diseases 2006 – Rem...

Disease advocacy organizations have long played an important role in the continuum from basic science to therapy development in rare disease research. PXE International has led the field in innovative ways, venturing into specific activities that have traditionally been conducted by scientists. As lay founders, we have engaged in gene discovery, gene patenting, diagnostic test development, epid...

The concept of the collaborative relationship between patient and therapist has its roots in the psychodynamic literature. We trace the concept of collaboration in psychodynamic psychotherapy from classical psychoanalysis to contemporary psychoanalysis and psychodynamic therapies. The active collaboration between the participants central to Bordin's pan-theoretical perspective on the alliance i...

The transition of new biotechnologies into clinical trials is a critical step in approving a new drug or therapy in health care. Ethically recruiting appropriate volunteers for these clinical trials can be a challenging task for both the pharmaceutical companies and the US Food and Drug Administration. In this paper we analyze the Jewish halachic perspectives of volunteering for clinical trials...

Despite extensive educational and preventive efforts, fatality from poisoning is a growing public health concern. While strategies to reduce fatal unintentional poisoning in children have been largely successful, growing numbers of deaths from suicidality and substance abuse present unique challenges to the public health system. This paper explores three areas where new approaches hope to mitig...